Mohs Surgery for the treatment of Lentigo Maligna and Lentigo Maligna Melanoma – A Systematic Review.

Mohs Surgery for the treatment of Lentigo Maligna and Lentigo Maligna Melanoma – A Systematic Review.

Publication date: Nov 07, 2019

BACKGROUND: The role of Mohs micrographic surgery (MMS) in the treatment of lentigo maligna (LM) and lentigo maligna melanoma (LMM) has been controversial. The use of frozen sections is commonly cited as a suboptimal way to distinguish atypical melanocytes, resulting in traditional wide-local excision techniques as the mainstay of therapy.OBJECTIVE: To compare the success of MMS as a treatment option for LM and LMM with that of traditional surgical and nonsurgical therapies by analyzing the published recurrence rates of these lesions after MMS procedures.METHODS & MATERIALS: PubMed database was used to find relevant articles with search terms related to MMS, LM, and LMM.RESULTS: The search strategy resulted in 27 articles that fulfilled the inclusion criteria. All studies considered, MMS provided a 1.35% recurrence rate with follow-up times ranging from 1 month – 5 years. Specifically, studies employing classical MMS and MMS with rush sections provided recurrence rates of 1.17% and 2.4%, respectively.CONCLUSION: MMS is one of the most successful treatment options for LM and LMM, with published evidence of improved recurrence rates when compared to other forms of therapy. Additional clinical trials are needed to further delineate the role of MMS in the treatment algorithm for these conditions.

Sharma, A.N., Foulad, D.P., Doan, L., Lee, P.K., and A Mesinkovska, N. Mohs Surgery for the treatment of Lentigo Maligna and Lentigo Maligna Melanoma – A Systematic Review. 24685. 2019 J Dermatolog Treat.

Concepts Keywords
Algorithm Melanoma
Clinical Trials Surgery
Lentigo Melanoma
Maligna Medicine
Melanocytes Organ systems
Melanoma Medical specialties
MMS Lentigo maligna
Mohs Micrographic Surgery Mohs surgery
Mohs Surgery
PubMed

Semantics

Type Source Name
disease MESH Lentigo Maligna
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
drug DRUGBANK Spinosad
disease MESH recurrence

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *